Abstract
Over the ages, humans have relied on nature for their basic needs for the production of foodstuffs, shelters, clothing, means of transportation, fertilizers, flavors and fragrances, and not least, medicines. Plants have formed the basis of sophisticated traditional medicine systems that have been in existence for thousands of years in countries such as China1 and India.2 These plant-basedsystems continue to play an essential role in health care, and it has been estimated by the World Health Organization that approximately 80% of the world’s inhabitants rely mainly on traditional medicines for their primary health care.3 Plant products also play an important role in the health care systems of the remaining 20% of the population mainly residing in developed countries. Analysis of data on prescriptions dispensed from community pharmacies in the United States from 1959 to 1980 indicates that about 25% contained plant extracts or active principles derived from higher plants, and at least 119 chemical substances, derived from 90 plant species, can be considered as important drugs currently in use in one or more countries.3 Of these 119 drugs, 74% were discovered as a result of chemical studies directed at the isolation of the active substances from plants used in traditional medicine. Well-known examples of plant-derived medicinal agents include: the antimalarial drug quinine, obtained from the bark of Cinchona officinalis; the analgesics, codeine and morphine from Papaver somniferum; the antihypertensive reserpine from Rauwolfia serpentina; and the cardiac glycoside, digoxin, from Digitalis purpurea.4
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
CHANG, H-M, BUT, PP-H. 1986. Pharmacology and Applications of Chinese Materia Medica, Vols 1 and 2, Singapore, World Scientific Publishing.
KAPOOR, L.D. 1990. CRC Handbook of Ayurvedic Medicinal Plants. Boca Raton, Florida, CRC Press.
FARNSWORTH, N.R., AKERELE, O., BINGEL, A.S., SOEJARTO, D.D., GUO, Z. 1985. Medicinal plants in therapy. Bull. WHO. 63: 965–981.
KINGHORN A.D. 1994. The discovery of drugs from higher plants. In: The Discovery of Natural Products with Therapeutic Potential (VP Gullo, ed.), Butterworth-Heinemann, Boston, pp. 81–108.
MCCONNEL, O., LONGLEY, R.E., KOEHN, F.E. 1994. The discovery of marine natural products with therapeutic potential. In: The Discovery of Natural Products with Therapeutic Potential (VP Gullo, ed.), Butterworth-Heinemann, Boston, pp. 109–174.
CRAGG, G.M., NEWMAN, D.J., SNADER, K.M. 1997. Natural products in drug discovery and development. J. Nat. Prod. 60: 52–60.
HARTWELL J.L. 1982. Plants Used Against Cancer. Quarterman, Lawrence, MA.
CRAGG, G.M., BOYD, M.R., CARDELLINA II, J.H., NEWMAN, D.J., SNADER, K.M., MCCLOUD, T.G. 1994. Ethnobotany and drug discovery: The experience of the US National Cancer Institute. In: Ethnobotany and the Search for New Drugs. Ciba Foundation Symposium 185, (DJ Chadwick, J Marsh, eds.), Wiley & Sons, Chichester, U.K., pp. 178–196.
DRISCOLL, J.S. 1984. The preclinical new drug research program of the National Cancer Institute. Cancer Treat. Rep. 68: 63–76.
POTMEISEL, M., PINEDO, H. 1995. Camptothecins: New Anticancer Agents. Boca Raton, Florida, CRC Press.
CRAGG, G.M., BOYD, M.R., CARDELLINA II, J.H., GREVER, M.R., SCHEPARTZ, S.A., SNADER, K.M., SUFFNESS, M. 1993. Role of plants in the National Cancer Institute drug discovery and development program. In: Human Medicinal Agents from Plants. Am Chem Soc Symposium Series 534, (AD Kinghorn, MF Balandrin, eds.), Amer. Chem. Soc, Washington, DC, pp. 80–95.
CHRISTIAN, M.C., PLUDA, J.M., HO, T.C., ARBUCK, S.G., MURGO, A.J., SAUSVILLE, E.A. 1997. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Sem. Oncol. 24: 219–240.
PHILIP, P.A., REA, D., THAVASU, P., CARMICHEL, J., STUART, N.S.A., ROCKETT, H., TALBOT, D.C., GANESAN, T., PETTIT, G.R., BALKWILL, F., HARRIS, A.L. 1993. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. J. Natl. Cancer Inst. 85: 1812–1818.
BOYD, M.R., PAULL, K.D. 1995. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34: 91–109.
MAYS, TD, MAZAN, K.D., CRAGG, G.M., BOYD, M.R. 1997. “Triangular privity”-a working paradigm for the equitable sharing of benefits from biodiversity research and development. In: Global Genetic Resources: Access, Ownership, and Intellectual Property Rights, (KE Hoagland and AY Rossman, eds.), Association of Systematics Collections, Washington DC, pp. 279–298.
BOYD, M.R. 1988. Strategies for the identification of new agents for the treatment of AIDS: A national program to facilitate the discovery and preclinical development of new candidates for clinical evaluation. In: “AIDS: Etiology, Diagnosis, Treatment and Prevention” (VT. De Vita, S. Hellman and S.A. Rosenberg, eds.), J.B. Lippincott, Philadelphia, pp. 305–319.
WEISLOW, O.S., KISER, R., FINE, D.L, BADER, J., SHOEMAKER, R.H., BOYD, M.R. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81: 577–586.
CRAGG, G.M., SCHEPARTZ, S.A., SUFFNESS, M., GREVER, M.R. 1993. The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J. Nat. Prod. 56: 1657–1668.
HORWITZ, S.B. 1992. Mechanism of action of taxol. Trends Pharmacol. Sci. 13: 134–136.
MCQUIRE, W.P., ROWINSKY, E.K., ROSENSHEIM, N.B., GRUMBINO, EC, CETTINGER, D.S., ARMSTRONG, D.K., DONEHOWER, R.C. 1989. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111: 273–279.
DENIS, J.N., GREENE, A.E., GUENARD, D., GUERITTE-VOEGELEIN, F., MANGATAL, L., POTIER, P. 1988. Highly efficient, practical approach to natural taxol. J. Am. Chem. Soc. 110: 5917–5919.
HOLTON, R.A., LIU, J.H., GENTILE, L.N., BEIDIGER, RJ. 1992. Semi-synthesis of taxol. Second NCI Workshop on Taxol and Taxus, Alexandria, VA, National Cancer Institute, September, 1992;
GEORG, G.I., CHERUVALLATH, Z.S., HIMES, R.H., MEJILLANO, M.R. 1992. Novel biologically active taxol analogues: Baccatin III 13-[N-p-chlorobenzoyl-(2′R,3′S)-3′-phenylisoserinate] and baccatin III 13[N-benzoyl-(2′,R,3′S)-3′,-(p-chlorophenyl)isoserinate]. Bioorg Med Chem Lett. 2: 295–298.
CORTES, J.E., PAZDUR, R. 1995. Docetaxel. J. Clin. Oncol. 13: 2643–2655.
Paclitaxel production, marketing heats up. Chem. & Eng. News, 1998, June 15:11
STROBEL, G.A., HESS, W.M., FORD, E., SIDHU, R.S., YANG, X. 1996. Taxol from fungal endophytes and the issue of biodiversity. J. Industrial Microbiology 17: 417–423.
BOYD, M.R., HALLOCK, Y.F., CARDELLINA, J.H., II, MANFREDI, K.P., BLUNT, J.W., MCMAHON, J.B., BUCKHEIT, R.W., JR., BRINGMANN, G., SCHAFFER, M., CRAGG, G.M., THOMAS, D.W, JATO, J.G. 1994. Anti-HIV michellamines from Ancistrocaldus korupensis. J. Med. Chem. 37: 1740–1745.
THOMAS, D.W., GEREAU, R.E. 1993. Ancistrocladus korupensis (Ancistroclada ceae): A New Species of Liana from Cameroon. Novon. 3: 494–498.
BRINGMANN, G., HARMSEN, S., HOLENZ, J., GEUDER, J., GOTZ, R., KELLER, P.A., WALTER, R., HALLOCK, Y.F., CARDELLINA, J.H., II, BOYD, M.R. 1994. “Biomimetic” oxidative dimerization of korupensamine A: Completion of the first total synthesis of michellamines A, B, and C. Tetrahedron. 50: 9643–9648.
HALLOCK, Y.F., MANFREDI, K.P., BLUNT, J.W., CARDELLINA, J.H., II, SCHAFFER, M., GLUDEN, K-P., BRINGMANN, G, LEE, A.Y., CLARDY, J., FRANCOIS, G., BOYD, M.R. 1994. Korupensamines A—D, novel antimalarial alkaloids from Ancistrocladus korupensis. J. Org. Chem. 59: 6349–6355.
SUFFINESS, M, CRAGG, G.M., GREVER, M.R., GRIFO, F.J., JOHNSON, G., MEAD, J.A.R., SCHEPARTZ, S.A., VENDITTI, J.M., WOLPERT, M. 1995. The National Cooperative Natural Products Drug Discovery Group (NCNPDDG) and International Cooperative Biodiversity Group (ICBG) Programs. Internat. J. Pharmacognosy. 33 Supplement: 5–16.
BAKER, J.T., BORRIS, R.P., CARTE, B, CRAGG. G.M., GUPTA, M.P., IWU, M.M., MADULID, D.R., TYLER, V.E. 1995. Natural product drug discovery and development: New perspectives on international collaboration. J. Nat. Prod. 58: 1325–1357.
KASHMAN, Y., GUSTAFSON, K.R., FULLER, R.W., CARDELLINA, J.H., II, MCMAHON, J.B., CURRENS, M.J., BUCKHEIT, R.W, HUGHES, S.H., CRAGG, G.M., BOYD, M.R. 1992. The Calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum langerum. J. Med. Chem. 35: 2735–2743.
FLAVIN, M.T., RIZZO, J.D., KHILEVICH, A., KUCHERENKO, A., SHEINKMAN, A.K., VILAYCHACK, V, LIN, L., CHEN, W., GREENWOOD, E.M., PENGSUPARP, T., PEZZUTO, J, HUGHES, S.H., FLAVIN, T.M., CIBULSKI, M., BOULANGER, W.A., SHONE, R.L., XU, Z.-Q. 1996. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (±)-calanolide A and its enantiomers. J. Med. Chem. 39: 1303–1313.
TENKATE, K, WELLS, A. 1998. Benefit-Sharing Case Study. The access and benefit-sharing policies of the United States National Cancer Institute: a comparative account of the discovery and development of the drugs Calanolide andTopotecan. Submission to the Executive Secretary of the Convention on Biological Diversity by the Royal Botanic Gardens, Kew.
ROSENTHAL, J. 1997. OECD Proceedings: Investing in Biological Diversity. The Cairns Conference, Australia, 25–28 March, 1996. OECD Publications, Paris, pp. 253–273.
BALANDRIN, M.F., KINGHORN, A.D., FARNSWORTH, N.R. 1993. Plant-derived natural products in drug discovery and development. An overview. In: Human Medicinal Agents from Plants (AD Kinghorn and MF Balandrin, eds.) Am. Chem. Soc. Symposium Series 534, Amer. Chem. Soc, Washington, DC, pp. 2–12.
YOUNG, P. 1997. Major microbial diversity initiative recommended. ASM News. 63: 417–421.
SAUSVILLE, E.A. 1997. Targeted toxins. In: Encyclopedia of Cancer, Vol. III. Academic Press, Inc., pp. 1703–1714.
MELTON, R.G., SHERWOOD, R.F. 1996. Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 88: 153–165.
MCDANIEL, R., EBERT-KHOSLA, S., HOPWOOD, D.A., KHOSLA, C. 1995. Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic units. Nature. 375: 549–554.
HORAN, A.C. 1994. Actinomycetes: A continuos source of novel natural products. In: The Discovery of Natural Products with Therapeutic Potential (VP Gullo, ed.), Butterworth-Heinemann, Boston, pp. 3–30.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cragg, G.M., Boyd, M.R., Khanna, R., Newman, D.J., Sausville, E.A. (1999). Natural Product Drug Discovery and Development. In: Romeo, J.T. (eds) Phytochemicals in Human Health Protection, Nutrition, and Plant Defense. Recent Advances in Phytochemistry, vol 33. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4689-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4689-4_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7123-6
Online ISBN: 978-1-4615-4689-4
eBook Packages: Springer Book Archive